Aktis Oncology, Inc. (AKTS)

NASDAQ: AKTS · Real-Time Price · USD

24.77

+0.67 (2.78%)

At close: Aug 11, 2026, 4:00 PM EDT

25.23

+0.46 (1.86%)

After-hours: Aug 11, 2026, 7:34 PM EDT

Aktis Oncology Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	6.5	6.5	1.49	-	-
Revenue Growth	-	336.92%	-	-	-
Gross Profit	6.5	6.5	1.49	-	-
Operating Income	-74.68	-74.68	-52.05	-34.79	-19.76
Net Income	-63.73	-63.73	-43.98	-28.64	-17.93
Earnings Per Share	-78.34	-78.34	-62.46	-46.56	-34.66
EPS Growth	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Investments	538.48	226.79	297.17	97.86	128.6
Total Debt	11.58	11.55	12.01	13.4	1.78
Net Cash (Debt)	526.91	215.24	285.16	84.46	126.82
Net Cash Growth	75.63%	-24.52%	237.63%	-33.40%	-
Net Cash Per Share	9.53	264.58	404.96	137.29	245.11

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Cash Flow	-64.13	-64.13	14.76	-30	-18.13
Capital Expenditures	-9.58	-9.58	-2.86	-3.76	-2.31
Free Cash Flow	-73.71	-73.71	11.9	-33.77	-20.43
Free Cash Flow Growth	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	-1149.52%	-1149.52%	-3500.34%	-	-
Pretax Margin	-980.93%	-980.93%	-2957.63%	-	-
Profit Margin	-980.93%	-980.93%	-2957.63%	-	-
FCF Margin	-1134.54%	-1134.54%	800.27%	-	-